Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab

Mayo Clinic Proceedings

Volumn 82, Issue 6, 2007, Pages 692-699

  Witzig, Thomas E ^a,b   Inwards, David J ^a   Habermann, Thomas M ^a   Dogan, Ahmet ^b   Kurtin, Paul J ^b   Gross Jr , John B ^b   Ananthamurthy, Anuradha ^b   Ristow, Kay M ^a   Garrity, James A ^b  

^a Division of Cardiovascular Surgery   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; DIPHENHYDRAMINE; METHOTREXATE; PARACETAMOL; PREDNISONE; RITUXIMAB;

ADULT; AGED; ARTICLE; BENIGN ORBITAL PSEUDOLYMPHOMA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; ORBIT PSEUDOTUMOR; OUTCOME ASSESSMENT; PSEUDOLYMPHOMA; TREATMENT FAILURE; TUMOR BIOPSY;

EID: 34249936959     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.6.692     Document Type: Article

References (76)

1. Knowles DM, Jakobiec FA, McNally L, Burke JS. Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): a prospective multiparametric analysis of 108 cases during 1977 to 1987. Hum Pathol. 1990;21:959-973.
2. Liesegang TJ. Ocular adnexal lymphoproliferative lesions. Mayo Clin Proc. 1993;68:1003-1010.
3. Coupland SE, Hellmich M, Auw-Haedrich C, Lee WR, Stein H. Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. Graefes Arch Clin Exp Ophthalmol. 2004 Feb;242:130-145. Epub 2003 Dec 18.
4. Sauerwein W, Hoederath A, Sack H. Radiotherapy of primary orbital lymphomas. Front Radiat Ther Oncol. 1997;30:192-194.
5. Kennerdell JS, Flores NE, Hartsock RJ. Low-dose radiotherapy for lymphoid lesions of the orbit and ocular adnexa. Ophthal Plast Reconstr Surg. 1999;15:129-133.
6. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16: 2825-2833.
7. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-2195.
8. Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW, IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol. 1999;62:76-82.
9. Tobinai K, Kobayashi Y, Narabayashi M, et al, IDEC-C2B8 Study Group. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Ann Oncol. 1998;9:527-534.
10. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101-106.
11. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005 Feb 20;23:1103-1108. Epub 2005 Jan 18.
12. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
13. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
14. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005 Feb 15;105:1417-1423. Epub 2004 Oct 19.
15. Habermann TM, Weller EA, Morrison VA. et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006 Jul 1;24:3121-3127.Epub 2006 Jun 5.
16. Hegde TJP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associaled immune thrombocytopenia in chronic lymphocytic leukemia. Blood. 2002;100:2260-2262.
17. Narat S, Gandla J, Hoffbrand AV, Hughes RG, Menta AB. Rituximab in the treatment of refractory autoimmune cytopenias in adults [letter]. Haematologica. 2005;90:1273-1274.
18. Scholllupf C, Kjedsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006; 47:253-260.
19. Leinweber B, Colli C, Chott A, Kerl H, Cerroni L. Differential diagnosis of cutaneous infiltrates of B lymphocytes with follicular growth pattern. Am J Dermatopathol. 2004;26:4-13.
20. Nolden S, Casper C, Kuhn A, Petereit HF. Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate. Mult Scler. 2005;11:245-248.
21. Dargent JL, Debois J, Sass U, Theunis A, Andre J, Simonart T. Unusual T cell Pseudolymphoma with features of so-called pseudolymphomatous folliculitis [letter]. Dermatology. 2002;204:159-161.
22. Arai E, Shimizu M, Hirose T. A review of 55 cases of cutaneous lymphoid hyperplasia: reassessment of the histopathologic findings leading to reclassification of 4 lesions as cutaneous marginal zone lymphoma and 19 as pseudolymphomatous folliculitis. Hum Pathol. 2005;36:505-511.
23. Dargent JL, De Wolf-Peeters C. Subcutaneous lymphoid hyperplasia arising at site of ethnic scarifications and mimicking subcutaneous panniculitis-like T-cell lymphoma: a subcuticular T-cell lymphoid dyscrasia [letter]. Virchows Arch. 2004 Apr;444:395-396. Epub 2003 Dec 2.
24. Dragonetti E, Cianchini G, Mastrangelo L, Mellone P, Baldi A. Cutaneus pseudolymphoma: a case report. In Vivo. 2004;18:549-551.
25. Kazakov DV, Burg G, Dummer R, Kempf W. Cutaneous lymphomas and pseudolymphomas: newly described entities. Recent Results Cancer Res. 2002;160:283-293.
26. Kazakov DV, Burg G, Kempf W. Primary cutaneous B-cell lymphomas and pseudolymphomas: review of histopathological features. Cesk Patol. 2002;38:147-154.
27. Gilliam AC, Wood GS. Cutaneous lymphoid hyperplasias. Semin Cutan Med Surg. 2000;19:133-141.
28. Scarisbrick JJ, Orchard G, Russell-Jones R. Lymphocytoma cutis with conjunctival lesions [letter]. Br J Ophthalmol. 1999;83:882.
29. Braun RP, French LE, Feldmann R, Chavaz P, Saurat JH. Cutaneous pseudolymphoma, lymphomatoid contact dermatitis type, as an unusual cause of symmetrical upper eyelid nodules. Br J Dermatol. 2000;143:411-414.
30. Boudova L, Kazakov DV, Sima R, et al. Cutaneous lymphoid hyperplasia and other lymphoid infiltrates of the breast mpple: a retrospective clinicopadiologic study of fifty-six patients. Am J Dermatopathol. 2005;27:375-386.
31. Shreve PD. Pseudolymphoma of the lung: benign pulmonary nodule with elevated fluorodeoxyglucose uptake. Clin Nucl Med. 2000;25:154-155.
32. Kajiwara S, Sakai S, Soeda H, et al. Multifocal nodular lymphoid hyperplasia of the lung. J Thorac-Imaging. 2005;20:239-241.
33. Travis WD, Galvin JR. Non-neoplastic pulmonary lymphoid lesions. Thorax. 2001;56:964-971.
34. Abbondanzo SL, Rush W, Bijwaard KE, Koss MN. Nodular lymphoid hyperplasia of the lung: a clinicopathologic study of 14 cases. Am J Surg Pathol. 2000;24:587-597.
35. Adsay NV, Basturk O, Klimstra DS, Kloppel G. Pancreatic pseudotumors: non-neoplastic solid lesions of the pancreas that clinically mimic pancreas cancer. Semin Diagn Pathol. 2004;21:260-267.
36. Donnet A, Horschowski N, Dufour H, et al. Intracranial pseudolymphoma. J Neurooncol. 2000;47:175-179.
37. Okubo H, Maekawa H, Ogawa K, et al. Pseudolymphoma of the liver, associated with Sjogren's syndrome. Scand J Rheumatol. 2001;30:117-119.
38. Telander DG, Lee TZ, Pambuccian SE, Huang AJ. Subconjunctival corticosteroids for benign lymphoid hyperplasia [letter]. Br J Ophthalmol. 2005;89:770-771.
39. Masruha MR, Marques CM, Vilanova LC, de Seixas Alves MT, Peres MF, Rodrigues MG. Drug induced pseudolymphoma secondary to ethosuximide [letter]. J Neurol Neurosurg Psychiatry. 2005;76:1610.
40. Dar NR, Shaheen, Mustafvi SA, Raza N. Cutaneous pseudolymphoma due to topical application of 4% hydroquinone cream for melasma. J Coll Physicians Surg Pak. 2005;15:496-497.
41. Choi TS, Doh KS, Kim SH, Jang MS, Sun KS, Kim ST. Clinicopathological and genotypic aspects of anticonvulsant-induced pseudolymphoma syndrome. Br J Dermatol. 2003;148:730-736.
42. Marucci G, Sgarbanti E, Maestri A, Calandri C, Collina G. Gemcitabine-associated CD8+ CD30+ pseudolymphoma. Br J Dermatol. 2001;143:650-652.
43. Cogrel O, Beylot-Barry M, Vergier B, et al. Sodium valproate-induced cutaneous pseudolymphoma followed by recurrence with carbamazepine. Br J Dermatol. 2001;144:1235-1238.
44. Wiesli P, Joos L, Galeazzi RL, Dummer R. Cutaneous pseudolymphoma associated with bromocriptine therapy [letter]. Clin Endocrinol (Oxf). 2000;53: 656-657.
45. Melzer M, Keane FM, Eykyn SJ, Breathnach SM. A pseudolymphomatous skin reaction secondary to flucloxacillin. J Infect. 2000;40:198-199.
46. Gerlini G, Mori M, Massi D, Pimpinelli N. Specific immune therapy-related cutaneous B-cell pseudolymphoma with following dissemination. J Eur Acad Dermatol Venereol. 2003;17:208-212.
47. Maubec E, Pinquier L, Viguier M, et al. Vaccination-induced cutaneous pseudolymphoma. J Am Acad Dermatol. 2005;52:623-629.
48. Stavrianeas NG, Katoulis AC, Kanelleas A, Hatziolou E, Georgala S. Papulonodular lichenoid and pseudolymphomatous reaction at the injection site of hepatitis B virus vaccination. Dermatology. 2002;205:166-168.
49. Lee MW, Choi JH, Sung KJ, Moon KC, Koh JK. A case of cutaneous pseudolymphoma associated with silicone injection [letter]. Acta Derm Venereol. 2004;84:312-313.
50. Peoc'h M, Duprez D, Grice G, Fabre-Bocquentin B, Gressin R, Pasquier B. Silicone lymphadenopathy mimicking a lymphoma in a patient with a metatarsophalangeal joint prosthesis. J Clin Pathol. 2000;53:549-551.
51. Chave TA, Mortimer NJ, Johnston GA. Simultaneous pseudolymphomatous and lichenoid tattoo reactions triggered by re-tattooing [letter]. Clin Exp Dermatol. 2004;29:197-199.
52. Kahofer P, El Shabrawi-Caelen L, Horn M, Kern T, Smolle J. Pseudolymphoma occurring in a tattoo. Eur J Dermatol. 2003;13:209-212.
53. Moreno-Ramirez D, Garcia-Escudero A, Rios-Martin JJ, Herrera-Saval A, Camacho F. Cutaneous pseudolymphoma in association with molluscum contagiosum in an elderly patient. J Cutan Pathol. 2003;30:473-475.
54. McComb ME, Telang GH, Vonderheid EC. Secondary syphilis presenting as pseudolymphoma of the skin. J Am Acad Dermatol. 2003;49(suppl):S174-S176.
55. Feinberg AS, Spraul CW, Holden JT, Grossniklaus HE. Conjunctival lymphocytic infiltrates associated with Epstein-Barr virus. Ophthalmology. 2000;107:159-163.
56. Hwong H, Jones D, Prieto VG, Schulz C, Duvic M. Persistent atypical lymphocytic hyperplasia following tick bite in a child: report of a case and review of the literature. Pediatr Dermatol. 2001;18:481-484.
57. Peretz E, Grunwald MH, Cagnano E, Halevy S. Follicular B-cell pseudolymphoma. Australas J Dermatol. 2000;41:48-49.
58. Amrith S. Antero-medial orbital masses associated with nasopharyngeal carcinoma. Singapore Med J. 2002;43:97-99.
59. Lozzi GP, Fargnoli MC, Peris K. A 72-year-old woman wim papules and nodules at the site of previous mastectomy. Arch Pathol Lab Med. 2005; 129:e167-e168.
60. Tonami H, Matoba M, Yokota H, Higashi K, Yamamoto I, Sugai S. CT and MR findings of bilateral lacrimal gland enlargement in Sjogren syndrome. Clin Imaging. 2002;26:392-396.
61. Butterfield JH, Bartley GB. Atypical periorbital xanthogranulomas associated with systemic benign lymphoepithelial lesions. Ophthal Plast Reconstr Surg. 1994;10:287-292.
62. Egan CA, Patel BC, Morschbacher R, Gerwels JW, Anderson RL. Atypical lymphoid hyperplasia of the eyelids manifesting as xanthelasma-like lesions. J Am Acad Dermatol. 1997;37(5, pt 2):839-842.
63. Lanuza Garcia A, Lopez Ramos AL, Pinto Bonilla JC, Rodriguez Pereira C, Cortes Vizcaino V. Management of lymphoid hyperplasia of the ocular adnexa [in Spanish]. Arch Soc Esp Oftalmol. 2005;80:353-358.
64. Dang YN, Shin IC, Gordon RA, Karcioglu ZA. Bilateral reactive lymphoid hyperplasia of the orbit in a child with Russell-Silver syndrome. J AAPOS. 2004;8:588-591.
65. Shields CL, Shields JA, Carvalho C, Rundle P, Smith AF. Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma. Ophthalmology. 2001;108:979-984.
66. Rofail M, Lee LR, Whitehead K. Conjunctival benign reactive lymphoid hyperplasia associated wim myopic scleral thinning. Clin Experiment Ophthalmol. 2005;33:73-75.
67. Kim P, Macken PL, Palfreeman S, Rawlinson WD, Martin F. Bilateral benign lymphoid hyperplasia of the conjunctiva in a paediatric patient. Clin Experiment Ophthalmol. 2005;33:285-287.
68. Ioannidis AS, Rai P, Mulholland B. Conjunctival lymphoid hyperplasia presenting with bilateral panuveitis. Am J Ophthalmol. 2005;139:566-568.
69. Tang J, Rodgers IR, Basham KL, Goh J. Rare case of exuberant benign lymphoid hyperplasia involving the conjunctiva, caruncle, and plica in a child wim tonsilar enlargement. J AAPOS. 2003;7:293-294.
70. Cockerham GC, Hidayat AA, Bijwaard KE, Sheng ZM. Re-evaluation of "reactive lymphoid hyperplasia of the uvea": an immunohistochemical and molecular analysis of 10 cases. Ophthalmology. 2000;107:151-158.
71. Johnson TE, Tse DT, Byrne GE Jr, et al. Ocular-adnexal lymphoid tumors: a clinicopathologic and molecular genetic study of 77 patients. Ophthal Plast Reconstr Surg. 1999;15:171-179.
72. Falkenhagen KM, Braziel RM, Fraunfelder FW, Smith JR. B-cells in ocular adnexal lymphoproliferative lesions express B-cell attracting chemokine 1 (CXCL13). Am J Ophthalmol. 2005;140:335-337.
73. Kulow BF, Cualing H, Steele P, et al. Progression of cutaneous B-cell pseudolymphoma to cutaneous B-cell lymphoma. J Cutan Med Surg. 2002 Nov-Dec;6:519-528. Epub 2002 Oct 31.
74. Keleti D, Flickinger JC, Hobson SR, Mittal BB. Radiotherapy of lymphoproliferative diseases of the orbit: surveillance of 65 cases. Am J Clin Oncol. 1992;15:422-427.
75. Bessell EM, Henk JM, Whitelocke RA, Wright JE. Ocular morbidity after radiotherapy of orbital and conjunctival lymphoma. Eye. 1987;1(pt 1):90-96.
76. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood. 2006 May 1;107:3639-3646. Epub 2006 Jan 10.